INSB400 / InSitu Biologics - LARVOL DELTA

A novel trans-lymphatic route of loco-regional treatment with a single injection providing two routes of treatment (EORTC-NCI-AACR 2024) - "Our multi-phase delivery matrix can carry a large payload of docetaxel and doxorubicin and gradually release (elute) the medicant out as far as 7 days (INSB400). Drug delivery matrix components migrated through lymphatic channels from the primary injection site and were demonstrated in lymph nodes proximal to the injection site at 14 days. This may represent a novel and secondary (trans-lymphatic) treatment beyond the local tumor injection site. Loading multiple drugs within a single injectate to treat a primary tumor and lymph nodes/lymphatics without systemic absorption may be possible."

Oncology • Skin Cancer